Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly population

被引:2
|
作者
Sutandhio, Silvia [1 ]
Furukawa, Koichi [1 ]
Kurahashi, Yukiya [1 ]
Marini, Maria Istiqomah [1 ]
Effendi, Gema Barlian [1 ]
Hasegawa, Natsumi [1 ]
Ishimaru, Hanako [1 ]
Nishimura, Mitsuhiro [1 ]
Arii, Jun [1 ]
Mori, Yasuko [1 ]
机构
[1] Kobe Univ, Ctr Infect Dis, Div Clin Virol, Grad Sch Med, 7-5-1 Kusunoki Cho,Chuo Ku, Kobe, Hyogo 6500017, Japan
关键词
COVID-19; Elderly; Omicron; Vaccination; Neutralizing antibody; EXPRESSION; FUSION;
D O I
10.1016/j.jiph.2023.05.004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Omicron variants with immune evasion have emerged, and they continue to mutate rapidly, raising concerns about the weakening of vaccine efficacy, and the very elderly populations are vulnerable to Coronavirus Disease 2019 (COVID-19). Therefore, to investigate the effect of multiple doses of mRNA vaccine for the newly emerged variants on these populations, cross-neutralizing antibody titers were examined against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants, including BQ.1.1 and XBB. Methods: Blood samples were taken from residents at four long-term care facilities in Hyogo prefecture, Japan (median age, 91 years), after 3rd (n = 67) and 4th (n = 48) mRNA vaccinations, from April to October 2022. A live virus microneutralization assay was performed to determine the neutralizing antibody titers in participants' sera.Results: After 3rd vaccination, cross-neutralizing antibody prevalence against conventional (D614G) virus, Delta, Omicron BA.2, BA.5, BA.2.75, BQ.1.1, and XBB were 100%, 97%, 81%, 51%, 67%, 4%, and 21%, respectively. After 4th vaccination, the antibody positivity rates increased to 100%, 100%, 98%, 79%, 92%, 31%, and 52%, respectively. The 4th vaccination significantly increased cross-neutralizing antibody titers against all tested variants. Conclusion: The positivity rates for BQ.1.1 and XBB increased after 4th vaccination, although the titer value was lower than those of BA.5 and BA.2.75.Considering the rapid mutation of viruses and the efficacy of vaccines, it may be necessary to create a system that can develop vaccines suitable for each epidemic in consideration of the epidemic of the virus.(c) 2023 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:1064 / 1072
页数:9
相关论文
共 46 条
  • [21] A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2
    Thimmiraju, Syamala Rani
    Adhikari, Rakesh
    Villar, Maria Jose
    Lee, Jungsoon
    Liu, Zhuyun
    Kundu, Rakhi
    Chen, Yi-Lin
    Sharma, Suman
    Ghei, Karm
    Keegan, Brian
    Versteeg, Leroy
    Gillespie, Portia M.
    Ciciriello, Allan
    Islam, Nelufa Y.
    Poveda, Cristina
    Uzcategui, Nestor
    Chen, Wen-Hsiang
    Kimata, Jason T.
    Zhan, Bin
    Strych, Ulrich
    Bottazzi, Maria Elena
    Hotez, Peter J.
    Pollet, Jeroen
    VACCINES, 2023, 11 (10)
  • [22] Retained avidity despite reduced cross-binding and cross-neutralizing antibody levels to Omicron after SARS-COV-2 wild-type infection or mRNA double vaccination
    Harthaller, Teresa
    Falkensammer, Barbara
    Bante, David
    Huber, Maria
    Schmitt, Melanie
    Benainouna, Habib
    Roessler, Annika
    Fleischer, Verena
    von Laer, Dorothee
    Kimpel, Janine
    Wuerzner, Reinhard
    Borena, Wegene
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [23] Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination
    Bonura, Floriana
    Genovese, Dario
    Amodio, Emanuele
    Calamusa, Giuseppe
    Sanfilippo, Giuseppa Luisa
    Cacioppo, Federica
    Giammanco, Giovanni Maurizio
    De Grazia, Simona
    Ferraro, Donatella
    VACCINES, 2022, 10 (06)
  • [24] Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents
    Wang, Zheng
    Li, Dan
    Chen, Yulu
    Sun, Yeping
    Jin, Changzhong
    Hu, Caiqin
    Feng, Yi
    Su, Junwei
    Ren, Li
    Hao, Yanling
    Wang, Shuo
    Zhu, Meiling
    Liu, Ying
    Qi, Jianxun
    Zhu, Biao
    Shao, Yiming
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [25] A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB
    Ding, Yuan
    Fan, Feng
    Xu, Xin
    Zhao, Gan
    Zhang, Xin
    Zhao, Huiyun
    Wang, Limei
    Wang, Bin
    Gao, Xiao-Ming
    VACCINES, 2023, 11 (04)
  • [26] Neutralizing antibody and T-cell responses against SARS-CoV-2 variants by heterologous CoronaVac/ChAdOx-1 vaccination in elderly subjects with chronic obstructive pulmonary disease
    Chaiwong, Warawut
    Takheaw, Nuchjira
    Pata, Supansa
    Laopajon, Witida
    Duangjit, Pilaiporn
    Inchai, Juthamas
    Pothirat, Chaicharn
    Bumroongkit, Chaiwat
    Deesomchok, Athavudh
    Theerakittikul, Theerakorn
    Limsukon, Atikun
    Tajarernmuang, Pattraporn
    Niyatiwatchanchai, Nutchanok
    Trongtrakul, Konlawij
    Chuensirikulchai, Kantinan
    Cheyasawan, Passaworn
    Liwsrisakun, Chalerm
    Kasinrerk, Watchara
    VACCINE, 2023, 41 (40) : 5901 - 5909
  • [27] Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients
    Higashimoto, Yuki
    Kozawa, Kei
    Miura, Hiroki
    Kawamura, Yoshiki
    Ihira, Masaru
    Hiramatsu, Hiroyuki
    Suzuki, Ryota
    Haga, Kei
    Takai-Todaka, Reiko
    Sawada, Akihito
    Katayama, Kazuhiko
    Yoshikawa, Tetsushi
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (06)
  • [28] A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
    I-Jung Lee
    Cheng-Pu Sun
    Ping-Yi Wu
    Yu-Hua Lan
    I-Hsuan Wang
    Wen-Chun Liu
    Joyce Pei-Yi Yuan
    Yu-Wei Chang
    Sheng-Che Tseng
    Szu-I Tsung
    Yu-Chi Chou
    Monika Kumari
    Yin-Shiou Lin
    Hui-Feng Chen
    Tsung-Yen Chen
    Chih-Chao Lin
    Chi-Wen Chiu
    Chung-Hsuan Hsieh
    Cheng-Ying Chuang
    Chao-Min Cheng
    Hsiu-Ting Lin
    Wan-Yu Chen
    Fu-Fei Hsu
    Ming-Hsiang Hong
    Chun-Che Liao
    Chih-Shin Chang
    Jian-Jong Liang
    Hsiu-Hua Ma
    Ming-Tsai Chiang
    Hsin-Ni Liao
    Hui-Ying Ko
    Liang-Yu Chen
    Yi-An Ko
    Pei-Yu Yu
    Tzu-Jing Yang
    Po-Cheng Chiang
    Shang-Te Hsu
    Yi-Ling Lin
    Chong-Chou Lee
    Han-Chung Wu
    Mi-Hua Tao
    Journal of Biomedical Science, 29
  • [29] Neutralizing antibody response to SARS-CoV-2 bivalent mRNA vaccine in SIV-infected rhesus macaques: Enhanced immunity to XBB subvariants by two-dose vaccination
    Faraone, Julia N.
    Wang, Xiaolwei
    Qu, Panke
    Zheng, Yi-Min
    Vincent, Eunice
    Xu, Huanbin
    Liu, Shan-Lu
    JOURNAL OF MEDICAL VIROLOGY, 2024, 96 (03)
  • [30] Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination
    Abdallah, Al-Ola
    Mahmoudjafari, Zahra
    Atieh, Tahani
    Ahmed, Nausheen
    Cui, Wei
    Shune, Leyla
    Mohan, Meera
    McGuirk, Joseph
    Remker, Cassie
    Foss, Margaret
    Karloff, Ellie
    Fitch, Heather
    Atrash, Shebli
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (05) : 458 - 464